Inventor
Bryan K. Chan
Inventor
San Carlos, CA, US
Overview
Patents· 21 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds34%
A61KPreparations for medical, dental or toiletry purposes32%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations32%
G06QInformation and communication technology [ict] specially adapted for administrative, commercial, financial, managerial or supervisory purposes2%
PatentTitleYear
11,074,653System and method for optimizing data processing in cloud-based, machine learning environments through the use of self organizing map202111,034,692Naphthyridines as inhibitors of HPK1202110,952,995Azaindoles as inhibitors of HPK1202110,407,424Naphthyridines as inhibitors of HPK120199,951,064Azaindazole compounds as inhibitors of T790M containing EGFR mutants20189,890,152'Aminopyrimidine compounds as inhibitors of T790M containing EGFR mutants'20189,212,173'Pyrazole aminopyrimidine derivatives as LRRK2 modulators'20159,212,186'Bicyclic pyrazole LRRK2 small molecule inhibitors'20159,145,402'Aminopyrimidine derivatives as LRRK2 modulators'20159,139,566'Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (PET) imaging for LRRK2'20158,815,882'Pyrazole aminopyrimidine derivatives as LRRK2 modulators'20148,809,331'Aminopyrimidine derivatives as LRRK2 modulators'20148,802,674'Aminopyrimidine derivatives as LRRK2 modulators'20148,796,296'Aminopyrimidine derivatives as LRRK2 modulators'20148,791,130'Aminopyrimidine derivatives as LRRK2 modulators'20148,569,281'Compounds and their administration for treating a neurodegenerative disease as well as a method for identifying a compound capable of inhibiting a kinase, such as LRRK'20138,563,540'Pyrido[3,2-d]pyrimidine PI3K delta inhibitor compounds and methods of use'20138,440,651'Pyrido[3,2-d]pyrimidine PI3K delta inhibitor compounds and methods of use'20138,394,796'Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use'20138,354,420'Aminopyrimidine derivatives as LRRK2 inhibitors'20138,173,650'Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use'2012Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2012–2021Patents assigned to GENENTECH INC (19)· patent assignee history
2012–2013Patents assigned to CASTANEDO GEORGETTE (3)· patent assignee history
2012–2013Patents assigned to CHAN BRYAN (3)· patent assignee history
2012–2018Based in San Carlos, CA, US· patent location history
2013–2014Patents assigned to CHAN BRYAN K (3)· patent assignee history
2013–2014Patents assigned to CHEN HUIFEN (3)· patent assignee history
2013–2014Based in Burlingame, CA, US· patent location history
2013Based in South San Francisco, CA, US· patent location history
2018–2021Based in Foster City, CA, US· patent location history
2021Based in East Meadow, NY, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| GENENTECH INC | 19 | 2012–2021 |
| CASTANEDO GEORGETTE | 3 | 2012–2013 |
| CHAN BRYANself | 3 | 2012–2013 |
| CHAN BRYAN Kself | 3 | 2013–2014 |
| CHEN HUIFEN | 3 | 2013–2014 |
Locations
| Location | Patents | Span |
|---|---|---|
| San Carlos, California, US | 13 | 2012–2018 |
| Foster City, California, US | 4 | 2018–2021 |
| Burlingame, California, US | 2 | 2013–2014 |
| East Meadow, New York, US | 1 | 2021 |
| South San Francisco, California, US | 1 | 2013 |